$33.48 0.6%
EXEL Stock Price vs. AI Score
Data gathered: February 9

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.


Exelixis
Price $33.48
Target Price Sign up
Volume 1,460,000
Market Cap $9.62B
Year Range $21.56 - $37.27
Dividend Yield 0%
PE Ratio 21.74
Analyst Rating 60% buy
Earnings Date February 11 '25
Industry Biotechnology

In the news


Insider Transactions View All

Hessekiel Jeffrey filed to sell 486,059 shares at $36.7.
December 2 '24
Haley Patrick J. filed to sell 278,665 shares at $35.3.
November 26 '24
Haley Patrick J. filed to sell 288,665 shares at $34.4.
November 19 '24
Haley Patrick J. filed to sell 308,046 shares at $34.3.
November 19 '24
Aftab Dana filed to sell 498,945 shares at $35.
November 7 '24

What is the Market Cap of Exelixis?

The Market Cap of Exelixis is $9.62B.

What is Exelixis' PE Ratio?

As of today, Exelixis' PE (Price to Earnings) ratio is 21.74.

When does Exelixis report earnings?

Exelixis will report its next earnings on February 11 '25.

What is the current stock price of Exelixis?

Currently, the price of one share of Exelixis stock is $33.48.

How can I analyze the EXEL stock price chart for investment decisions?

The EXEL stock price chart above provides a comprehensive visual representation of Exelixis' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Exelixis shares. Our platform offers an up-to-date EXEL stock price chart, along with technical data analysis and alternative data insights.

Does EXEL offer dividends to its shareholders?

As of our latest update, Exelixis (EXEL) does not offer dividends to its shareholders. Investors interested in Exelixis should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Exelixis?

Some of the similar stocks of Exelixis are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.